GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment for multiple myeloma (MM). The health ...

GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with combo regimens. Read more here.

GSK’s Blenrep combinations receives Japanese approval for treatment of relapsed/refractory multiple myeloma London, UK Tuesday, May 20, 2025, 12:00 Hrs [IST] GSK plc announced the approval of Blenrep ...

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat multiple myeloma in adults. The drug has been authorised ...

Blenrep combinations are currently under review in 14 countries, including the U.S., with a Prescription Drug User Fee Act (PDUFA) date of 23 July 2025.

Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma · Superior efficacy shown in two head-to-head phase III trials, including overall survival ...

Blenrep combo nearly tripled PFS to 36.6 months vs 13.4 months in DREAMM-7. Blenrep cut risk of death by 42% vs comparator in DREAMM-7 at 39.4-month median follow-up. Feel unsure about the market ...

The approval of Blenrep in the UK is a significant step for multiple myeloma treatment, with further international approvals anticipated throughout 2025. This development is part of GSK’s ...

A no-frills hoodie that isn’t too light or too heavy goes. This will go with everything from your sweats and leggings to your jeans, dresses, and skirts. Sizes: XXS-2XL Colors: Coal, Parchment ...

GSK ’s GSK -0.32% blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return to market next year. The data ...

The safety profile of the Blenrep combination was consistent with previous analyses, with manageable and resolvable eye-related side effects, leading to a low treatment discontinuation rate. The trial ...